16/04/2021
RBD-specific polyclonal F(ab)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial
Waldo H. Belloso, Gustavo Lopardo; Esteban Nannini, Mariana Colonna, Santiago Sanguineti, Vanesa Zylbermane, Luciana Muñoz, Martín Dobarro, Gabriel Lebersztein, Javier Farina, Gabriela Vidiella, Anselmo Bertetti, Favio Crudo, Maria Fernanda Alzogaraym, Laura Barcelonaa, Ricardo Teijeiron, Sandra Lamberto, Darío Scublinskyp, Marisa Iaconoq, Vanina Stanek, Ruben Solari, Pablo Cruz, Marcelo Martín Casas, Lorena Abusamra, Hector Lucas Luciardi, Alberto Cremona, Diego Caruso, Bernardo de Miguel, Santiago Perez Llorete, Susana Millan, Yael Kilsteina, Ana Pereiro, Omar Sued, Pedro Cahn, Linus Spatz, Fernando Goldbaum on behalf of INM005 Study Group.